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Abstract
Introduction: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC)
in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine
the presence of and alterations in DTC- and CTC-status in locally advanced breast cancer patients undergoing
neoadjuvant chemotherapy (NACT) and to evaluate their prognostic impact.
Methods: Bone marrow and peripheral blood were collected before NACT (BM1: n = 231/PB1: n = 219), at surgery
(BM2: n = 69/PB2: n = 71), and after 12 months from start of NACT (BM3: n = 162/PB3: n = 141). Patients were
included from 1997 to 2003 and followed until 2009 (or ten years follow-up). DTC- and CTC-status were
determined by morphological evaluation of immunocytochemically detected cytokeratin-positive cells. The
prognostic significance of DTCs/CTCs was assessed by univariate and multivariate Cox-regression analyses.
Results: Before NACT, DTCs and CTCs were detected in 21.2% and 4.9% of the patients, respectively. At surgery,
15.9% and 1.4% had DTC- and CTC-presence, compared to 26.5% and 4.3% at 12 months from start of NACT. Of
patients for whom DTC results both before NACT and at 12 months were available, concordant results were
observed in 68%, and 14 out of 65 had positive DTC-status at both time points. Presence of ≥ 1 DTC 12 months
from start of NACT, but not at other time points, predicted reduced disease-free survival (DFS; HR 2.3, p = 0.003),
breast cancer-specific survival (BCSS; HR 3.0, p < 0.001) and overall survival (OS; HR 2.8, p < 0.001). Before NACT,
presence of ≥ 3 DTCs was also associated with unfavorable outcome, and reduced BCSS was observed for CTC-
positive patients (HR 2.2, p = 0.046). In multivariate analysis, DTC status (</≥ 1 DTC) at 12 months after start of
NACT remained as a prognostic factor for both DFS (HR 2.2, p = 0.005), BCSS (HR 2.6, p = 0.002) and OS (HR 2.6,
p = 0.002). The survival for patients with change in DTC-status was determined by the DTC-status at 12 months.
Conclusion: Presence of DTCs after NACT indicated high risk for relapse and death, irrespective of the DTC-status
before treatment. The results supports the potential use of DTC analysis as a monitoring tool during follow up, for
selection of patients to secondary treatment intervention within clinical trials.
Introduction
Despite earlier detection of breast cancer, a substantial
number of patients are diagnosed with locally advanced
disease. Larger tumor sizes, lymph node spread, and
unfavorable tumor biology all contribute to higher risk
of micrometastases at the time of diagnosis [1].
Increased use of systemic treatment, based on combined
use of prognostic and predictive factors, has resulted in
improved survival for all stages of early breast cancer
[2]. However, there is still need for additional markers
to guide clinical decision making.
During the last decade, disseminated tumor cells
(DTCs) in the bone marrow (BM) at the time of diagno-
sis have been shown to be an independent prognostic
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factor in early stage breast cancer [3]. In addition, per-
sistence of DTCs after a median relapse-free follow-up
interval of three years indicated an elevated risk of
relapse [4,5]. In contrast to primary tumor markers, ana-
lysis of DTCs may be used in the follow-up situation as
a surrogate marker to identify patients with a poor
response to adjuvant therapy. However, only a few smal-
ler studies have tested the significance of DTCs early
after completion of chemotherapy, with inconsistent
results [6,7]. In metastatic breast cancer, detection and
persistence (during therapy) of circulating tumor cells
(CTCs) identifies patients with an especially poor prog-
nosis [8-12]. More recently, CTCs have been shown to
be associated with a worse prognosis also in patients
with non-metastatic breast cancer [13-17].
The aim of neoadjuvant chemotherapy (NACT) is to
reduce tumor size prior to surgery and eradicate micro-
metastases. Today, the evaluation of the effect of this
therapy is based on the assessment of local tumor
response measured by clinical assessment, imaging mod-
alities and histopathological examination after breast sur-
gery. While a pathological complete response (pCR) after
neoadjuvant treatment is associated with improved long-
term prognosis [18], at least for certain subgroups of
breast cancer [19,20], there is still a need for novel tools
and surrogate markers for assessment of the adjuvant
treatment efficacy. Analysis of the fate of DTCs and
CTCs during and after treatment can give information
on the presence and load of minimal residual disease at
distant sites and indicate the need for optimized
treatment.
The primary aim of this study (The Neotax Study) was
to identify markers predicting drug resistance to epirubicin
versus paclitaxel monotherapy in locally advanced breast
cancer. The results related to antitumor response, disease-
free survival (DFS) and breast cancer-specific survival
(BCSS) have been published earlier [21,22]. In a separate,
predefined substudy, we explored the changes and prog-
nostic impact of DTCs and CTCs at different time points
during treatment and follow-up, and correlated these find-
ings to other clinicopathological parameters.
Materials and methods
Patients
The Neotax Study enrolled a total of 260 patients with
stage III/IV breast cancer on an intention-to-treat basis.
The study was a national study including participation by
all the Norwegian University hospitals [21,22]. Out of
these, a total of 236 patients signed separate informed
consent forms for participation in the micrometastasis
substudy of disseminated tumor cells and circulating
tumor cells. The study protocol was approved by the
Regional Ethical Committee (Norwegian Health Region
III). The recruitment period was between November
1997 and December 2003. The patients were followed
until October 2009, or maximally for 10 years or until
death.
Patients with locally advanced non-inflammatory breast
cancer (cT3-4 and/or cN2) were included in the study.
The routine diagnostic workup included mammography,
a surgical biopsy of the primary tumor, radiographs of
the chest, pelvic area and lumbar spine, ECG, liver ultra-
sound, bone scintigraphy, blood samples and clinical
examination including caliper measurement of the pri-
mary tumor. This was performed before starting the
neoadjuvant chemotherapy. The protocol allowed inclu-
sion of patients with limited distant metastases (that is,
locoregional metastases, limited skeletal metastases with
alkaline phosphatase (ALP) ≤ double the upper normal
limit or solitary lung or liver metastases for whom, in the
opinion of the investigator, their local tumor represented
the major therapeutic challenge). BM aspiration was not
performed if metastastasis was present in the iliac crest.
The patients were followed at each of the hospital’s out-
patient departments with clinical examination, mammo-
graphy, blood samples and chest radiograph on an
annual basis.
Treatment protocol
The Neotax study was an open-labeled multicenter study
in which patients were randomly allocated to treatment
with paclitaxel 200 mg/m2 (n = 129) or epirubicin
90 mg/m2 (n = 131) administered every third week. Of
the patients included in the DTC/CTC substudy, 115
were treated with paclitaxel and 121 with epirubicin. The
effects of treatment on the primary tumor were graded
by the UICC system [23] and not the newer RECIST cri-
teria [24] since the implementation of the protocol was
in October 1997. Thus, responses were classified as com-
plete response (CR), that is, complete disappearance of
all tumor lesions; partial response (PR), that is, ≥ 50%
reduction in the sum of all tumor lesions calculated for
each as the product of the largest diameter and the one
perpendicular to it; progressive disease (PD), that is,
increase in the diameter product of any individual tumor
lesion by ≥ 25%), or stable disease (SD), that is, anything
between PR and PD). A crossover between the treatment
arms was performed if there was no response (that is, SD
or PD after three to four courses). Chemotherapy was
followed by mastectomy and level 1 and 2 axillary clear-
ance. After surgery, the patients received locoregional
radiotherapy against the chest wall, ipsilateral axilla and
supraclavicular fossa (48 or 50 Gy depending on current
local practice). In case of tumor infiltration at the edge of
the specimen, a boost up to 10 Gy was applied to the
tumor bed in accordance with general practice. All
patients with estrogen receptor (ER)-positive tumors (n =
123) were given tamoxifen 20 mg × 1 for five years,
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except for postmenopausal women who were on tamoxi-
fen treatment up to mid-2004. According to the change
in the Norwegian Breast Cancer Group guidelines for
adjuvant endocrine therapy, these patients all switched to
three years treatment of aromatase-inhibitor after com-
pleting two to five years of tamoxifen treatment [25].
Bone marrow aspiration and peripheral blood collection
BM aspiration (bilateral iliac crest aspirates) and periph-
eral blood (PB) samples were obtained for analysis of
DTCs/CTCs at three time points: prior to commence-
ment of chemotherapy (BM1, n = 231 and PB1, n = 219),
on the day of mastectomy (BM2, n = 69 and PB2, n =
71), and 12 months after the day of randomization (BM3,
n = 162 and PB3, n = 141). The study was run by oncolo-
gists, and surgeons were encouraged to perform BM
aspirations at surgery (BM2). Logistical reasons and
variability in the surgeon’s motivations or skills was the
reason for the low number of samples collected at sur-
gery. To avoid any influence on the CTC or DTC results
from possible tumor cell-shedding during surgery, BM
and blood samplings were performed prior to surgery.
Analysis of primary tumor and axillary lymph nodes
The initial (pretreatment) surgical biopsy of the primary
tumor and primary tumor or axillary lymph nodes
resected at final surgery were processed on a routine
diagnostic basis. Histological tumor type, grade, hormone
receptor status, tumor size at the time of surgery, in addi-
tion to lymph node involvement, were analyzed. Tumors
were analyzed for estrogen receptors (ER) and progester-
one receptors (PgR) by immunohistochemistry and were
considered positive if > 10% of tumor cells stained posi-
tive with anti-ER- and/or anti-PgR antibodies, according
to standard procedure in Norway at the time of the
study. HER2 status is unknown because this was not a
part of the routine analyses at the time of the study.
BM aspiration and PB sampling
For each sampling, a total of 30 to 40 ml of BM was bilat-
erally aspirated from the posterior iliacal crest under
local anesthetic, and 50 ml of peripheral blood was col-
lected from each patient. The processing and analysis of
DTCs and CTCs have been previously described [26].
Briefly, after separation by Ficoll-Hypaque density centri-
fugation, mononuclear cells (MNC) were collected and
cytospins prepared (8 slides with 0.5 × 106 MNC/slide).
Four slides (2 × 106 MNC) were incubated with the
anticytokeratin monoclonal antibodies (mAbs) AE1 and
AE3 (Sanbio, Uden, the Netherlands). For each sample,
the same number of slides was incubated with an irrele-
vant monoclonal antibody of the same immunoglobulin
isotype (MOPC21, Sigma-Aldrich, Saint Louis, Missouri,
USA), as a negative control. For detection of mAb-bound
cells, the standard alkaline phosphate/antialkaline phos-
phatase (APAAP) method [27] with New Fuchsin as
chromogen, was used. The slides were counterstained
with heamotoxylin to visualize the morphology of the
nucleus.
Detection of CTCs/DTCs
The cytospins were manually screened with a light
microscope (x 10 lens) by a pathologist. The immunos-
tained cells that met certain predefined morphological
criteria [28], were scored as DTCs or CTCs. Patient sam-
ples harboring one or more cells that were characterized
as malignant, were considered positive. Samples harbor-
ing cells scored as tumor cells in both AE1AE3-incubated
slides and in the corresponding negative control slides
were considered as not evaluable and excluded from
conclusion.
Statistical analysis
Breast cancer-specific survival (BCSS) and overall survival
(OS) was measured from the date of randomization to
death from breast cancer or any death, otherwise censored
at the time of the last follow-up visit or at non-cancer
related death (for BCSS). Disease-free survival (DFS) was
measured the same way, according to the presence of
locoregional or systemic relapse, and was only analyzed in
patients without metastases (M0 patients). Kaplan-Meier
survival curves for time to distant recurrences and breast
cancer-specific death were constructed. P-values were
computed by the log-rank test. Cox proportional hazard
regression was used for univariate and multivariate analy-
sis of prognostic impact of relevant variables. For statistical
analysis, SPSS (PASW Version 18; SPSS, Chicago, Illinois,
USA) software was used.
Results
Patient characteristics and detection of DTCs and CTCs
A total of 260 patients were included in the study on an
intention-to-treat basis. Of these, 236 accepted participa-
tion in the micrometastasis substudy (Figure 1). Descrip-
tive clinical, histopathological and CTC/DTC data of the
patients enrolled are presented in Table 1. The median
age at diagnosis was 51 years. The immunocytochemical
(ICC) analysis disclosed ≥ 1 DTC/2 × 106 MNC in 21.2%
of the patients before neoadjuvant chemotherapy
(NACT) (at BM1). After 12 months from the start of
NACT (BM3), 26.5% of the patients were DTC-positive.
Sixty-nine patients had BM aspiration performed at sur-
gery (BM2), with presence of DTCs in eleven patients
(15.9%). No association was found between DTC status
and primary tumor characteristics. Of those that had BM
aspiration at BM1 and BM3, concordant results were
observed in 68% of the patients. Fourteen of the 65
patients who were positive at BM1 and/or BM3 (22%),
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had presence of DTC at both occasions (Table 1). The
incidence of CTCs before NACT was 4.9% compared to
1.4% and 4.3% on sampling at PB2 and PB3, respectively.
Association between DTC or CTC and clinical endpoints
The presence of ≥ 1 DTCs was not associated with tumor
response to chemotherapy at the time of diagnosis, at the
time of surgery, or 12 months after the start of NACT
(Table 1). Clinical outcomes were registered for 12 years
from study start or 10 years maximal follow-up. Ninety-
eight of the M0 patients (46.4%) experienced a relapse.
Out of these, 94 had a distant relapse, including 18 with
both distant and locoregional relapse (Table 1). Breast
cancer death was observed in 106 patients (including 20
patients with limited distant metastases at the time of
inclusion (M1 patients).
Table 2 presents the univariate survival analyses
according to DTC/CTC status and primary tumor char-
acteristics. Presence of ≥ 1 DTCs at BM1 did not have
any influence on DFS among the M0 patients (Figure 2).
Also, there was no association between the presence of
DTCs at BM2 and clinical outcomes (Table 2). However,
presence of ≥ 1 DTC at BM3 predicted reduced DFS (P =
0.003), BCSS (P < 0.001), and OS (P < 0.001) as also
shown in Figure 2. The analysis of BCSS and OS also
included patients with limited M1 status. No difference
Inclusion to DTC/CTC study 
N=236 
Sampling of BM/PB before 
NACT   
Not performed* 
BM: n=5 
PB: n=17 
Sampling of BM/PB  
1 year after start of NACT 
Clinical follow-up 
35 end of study  
• 34 relapse or death 
• 1 patient non-adherence 
BM1: n=231 
PB1: n=219 
 
BM3: n=162 
PB3: n=141 
 
Not performed* 
BM: n=39 
PB: n=60 
Sampling of BM/PB at surgery  
BM2: n=69 
PB2: n=71 
*Not performed because of 
patient refusal, unsuccessful 
sampling or logistical reasons 
Figure 1 Study overview of patients and samples at the different time points. Bone marrow (BM) aspiration and peripheral blood (PB)
sampling performed pretreatment (BM1 and PB1), at surgery (BM2 and PB2), and 12 months after start of neoadjuvant treatment (BM3 and PB3).
NACT, neoadjuvant chemotherapy.
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Table 1 Clinicopathological data and DTC status at BM1 and BM3
Variable Number of patients (N) DTC+ at BM1
n/number assessedd (%)
P-value DTC+ at BM3
n/number assessedd (%)
P-value
Total number 236 49/231 (21.2) 43/162 (26.5)
Median age, years (range) 51 (25-70)
cT status: 0.471b 0.659b
cT0-cT3 187 37/183 (20.2) 36/132 (27.3)
cT4 49 12/48 (25.0) 7/30 (23.3)
cN status 0.654b 0.203b
cN0 98 19/95 (20.0) 15/69 (21.7)
cN1 104 21/103 (20.4) 20/74 (27.0)
cN2-4 34 9/33 (27.3) 8/19 (42.1)
M status 0.162b 0.109ª
M1 25 8/25 (32.0) 6/13 (46.2)
M0 211 41/206 (19.9) 37/149 (24.8)
Hormone receptor status
Estrogen receptor 0.332ª 0.816ª
ER-pos 133 32/131 (24.4) 27/101 (26.7)
ER-neg 98 16/95 (16.8) 16/58 (27.6)
Unknown 5
Progesterone receptor 0.072ª 0.478ª
PgR-pos 113 30/110 (27.3) 26/88 (29.5)
PgR-neg 118 18/116 (15.5) 16/71 (22.5)
Unknown 5
Histological grade 0.666b 0.960ª
Grade 1 14 4/13 (30.8) 3/12 (25.0)
Grade 2 98 21/96 (21.9) 20/72 (27.8)
Grade 3 110 22/108 (20.4) 18/72 (25.0)
Unknown 14
Response 1.000ª 0.784ª
Complete response 10 2/10 (20.0) 1/6 (16.7)
Partial response 108 22/104 (21.2) 19/79 (24.1)
Stable disease 88 18/87 (20.7) 15/61 (24.6)
Progression 6 1/6 (16.7) 1/2 (50.0)
Unknown 24
BM1 status (pretreatment) 0.077b
Positive 49 14/37 (37.8)
Negative 182 28/121 (23.1)
Unknown 5
BM2 status (at surgery) 1.000ª 0.654ª
Positive 11 2/11 (18.2) 1/7 (14.3)
Negative 58 9/55 (16.4) 12/38 (31.6)
Unknown 167
BM3 status (at 1 year follow-up) 0.077b
Positive 43 14/42 (33.3)
Negative 119 23/116(19.8)
Unknown 74
PB1 status (pretreatment) 0.033ª 0.464ª
Positive 10 5/10 (50.0) 1//2 (50.0)
Negative 209 39/204 (19.1) 39/148 (26.4)
Unknown 17
PB2 status (at surgery) 1.000ª 0.298ª
Positive 1 0/1 (0) 1/1 (100.0)
Negative 70 12/67 (17.9) 13/46 (28.2)
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Table 1 Clinicopathological data and DTC status at BM1 and BM3 (Continued)
Unknown 165
PB3 status (at 1 year follow-up) 0.618ª 0.004ª
Positive 6 2/6 (33.3) 5/6 (83.3)
Negative 135 29/131 (22.1) 30/133 (22.6)
Unknown 95
Relapsec 0.642b 0.005b
Yes 98 22/98 (22.4) 22/55 (40.0)
No 112 21/107 (19.6)
Relapse type
Locoregional only 4 0/4 (0) 0/2 (0)
Distant metastases (skeletal
and/or visceral)
76 18/74 (24.3) 15/42 (35.7)
Distant metastases and
locoregional
18 4/18 (22.2) 7/11 (63.6)
Death and causee
Breast cancer death 106 23/105 (21.9) 26/53 (49.1)
Any death 111 25/110 (22.7) 27/57 (47.4)
Alive 124 24/120 (20.0) 16/105 (15.2)
ªP-value computed by Fisher’s exact test. bP-value computed by Pearson Chi-square. cRelapse data only for M0. dThe denominator (number assessed) for all
fractions in the table represents the number of patients with known DTC status (positive or negative) for the respective parameter. eNo information available
from one patient due to non-adherence.cT: clinical tumor status, cN: clinical lymph node status, M status: metastases status, DTC: disseminated tumor cells, BM:
bone marrow, PB: peripheral blood.
Table 2 Univariate survival analyses according to primary tumor factors and DTC/CTC status
DFSª (n = 211) BCSSb (n = 236) OS (n = 236)c
HR 95% CI P HR 95% CI P HR 95% CI P
DTC status
BM1-pos vs. BM1-neg 1.1 0.7-1.8 0.602 1.0 0.7-1.7 0.857 1.1 0.7-1.7 0.671
BM2-pos vs. BM2-neg 1.3 0.6-3.1 0.480 1.2 0.5-2.9 0.715 1.2 0.5-2.9 0.715
BM3-pos vs. BM3-neg 2.3 1.3-3.9 0.003 3.0d 1.8-5.2d < 0.001d 2.8e 1.7-4.7e < 0.001e
cN status (vs. cN0) 0.001 < 0.001 < 0.001
cN1 2.1 1.3-3.3 0.001 2.3 1.5-3.6 < 0.001 2.2 1.4-3.4 < 0.001
cN 2-4 2.5 1.4-4.5 0.003 3.0 1.7-5.3 < 0.001 2.8 1.6-4.8 < 0.001
Hormone receptor status
PgR-pos vs. PgR-neg 1.6 1.0-2.3 0.034 2.0 1.4-2.8 < 0.001 1.8 1.3-2.6 0.001
ER-pos vs. ER-neg 1.7 1.2-2.6 0.007 1.9 1.3-2.6 < 0.001 1.8 1.3-2.5 0.001
Histological grade
Grade 3 vs. grade 1-2 1.4 1.1-1.7 0.003 1.4 1.2-1.7 0.001 2.0 1.3-3.0 0.001
cT status
cT4 vs. cTX-3 1.1 0.7-1.9 0.584 1.3 0.8-2.0 0.226 1.4 0.9-2.1 0.151
CTC status
PB1-pos vs. PB1-neg 2.0 0.8-4.8 0.146 2.2f 1.0-4.8f 0.046f 2.1g 1.0-4.6g 0.057g
PB2 pos vs. PB2-neg 1.8 0.2-13.5 0.551 1.6 0.2-12.0 0.631 1.6 0.2-12.0 0.631
PB3-pos vs. PB3-neg 1.6 0.5-5.1 0.434 2.0 0.6-6.4 0.258 1.8 0.6-5.9 0.318
Clinical response
No CR vs. CR 1.2 0.5-2.9 0.737 1.2 0.5-3.0 0.651 1.2 0.5, 2.9 0.727
ªDisease-free survival (DFS) only for M0 patients.
bBreast cancer specific survival (BCSS) for all patients.
cOverall survival (OS) for all patients.
dBCSS according to bone marrow aspiration at BM3 analyzed for M0 patients only: hazard ratio (HR) 2.6, 95% CI 1.4-4.6, P = 0.002.
eOS according to BM3 status analyzed for stage M0 patients only: HR 2.4, 95% CI 1.4-4.2, P = 0.003.
fBCSS according to peripheral blood sampling at PB1 analyzed for stage M0 patients only: HR 2.1, 95% CI 0.8-5.1, P = .116.
gOS according to PB1 status analyzed for stage M0 patients only: HR 2.0, 95% CI 0.8-4.9, P = 0.142.
BM1, BM2 and BM3: bone marrow aspiration pre-treatment, at surgery, and 12 months after start of neoadjuvant treatment respectively.
cT: clinical tumor status; cN: clinical lymph node status; M0: no metastases present; DTC: disseminated tumor cells; CTC: circulating tumor cells; CR: complete response.
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Figure 2 Survival analyses according to disseminated tumor cell (DTC) status. Kaplan-Meier plots for disease-free survival (DFS) (A), breast
cancer specific survival (BCSS) (C) and overall survival (OS) (E) according to DTC status pretreatment (bone marrow aspiration 1 (BM1). DFS (B),
BCSS (D) and OS (F) according to DTC status 12 months after start of neoadjuvant therapy (BM3). DTC+, ≥ 1 cytokeratin-positive cell per 2 × 106
MNC. DTC-, no cytokeratin-positive cells detected.
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in the results was observed after exclusion of these
patients (25 and 13 of those analyzed at BM1 and BM3,
respectively; BCSS according to DTC status at BM3:
hazard ratio (HR) 2.6, P = 0.002). The presence of ≥ 1
CTC at PB1 was associated with BCSS (P = 0.046), but
not DFS (P = 0.146) (Table 2). Presence of CTCs at PB2
and PB3 did not affect survival. Achievement of CR was
not associated with clinical outcomes (Table 2).
Multivariate survival analysis
Factors associated with prognosis on univariate analysis
(Table 2) were included in a multivariate analysis (Table 3).
DTC status at BM3 remained a significant prognostic fac-
tor for both DFS (HR 2.2, P = 0.005), BCSS (HR 2.6, P =
0.002) and OS (HR 2.6, P = 0.002), besides lymph node (N)
status.
Other subgroup analyses
Patients with DTCs were grouped according to the num-
ber of DTCs present (Figure 3). The results showed that
patients with ≥ 10 DTCs at BM3 had detrimental DFS,
BCSS and OS. Also, patients with 1, 2, or 3 to 9 DTCs
experienced markedly reduced survival compared to those
with no DTCs (P < 0.001). There were no significant out-
come differences between these DTC-positive subgroups
for BCSS and OS. At BM1, presence of 3 to 9, or ≥ 10
DTCs negatively affected survival (Figure 3). Comparing
patients with 0 to 2DTCs versus ≥ 3 DTCs, a significant
difference in DFS (HR 2.4, 95% confidence interval (CI)
1.03 to 5.4, P = 0.043) and in BCSS (HR 2.4, 95% CI 1.2 to
4.9, P = 0.011) was observed.
To disclose the clinical significance of the DTC status
at different time points, we combined the results from
BM1 and BM3 (Figure 4). BM2 results were not included
in this analysis, because of the relatively low number of
patients with DTC status available at this time point. The
results showed that presence of DTCs at BM1 only was
unfavorable if DTCs persisted at BM3. Patients with a
switch from positive to negative had similar prognosis to
those with no DTC present at both time points. Regard-
ing the CTC status, the positivity rate was too low for
further subgroup analyses.
The number of patients analyzed for DTCs was
reduced from 231 at BM1 to 162 at BM3 due to a combi-
nation of patient refusal or unsuccessful BM aspiration
(n = 39), or relapse or death (n = 34) before this time
point. One patients was excluded because of refusal to
undergo postoperative radiotherapy (n = 1). We therefore
performed additional survival analyses according to BM1
status for patients with no available DTC result at BM3.
The data showed no survival difference between the
DTC-positive (≥ 1 cell) and DTC-negative group (DFS:
HR 0.9, 95% CI 0.4 to 2.1, P = 0.823 and BCSS: HR 1.2,
95% CI 0.6 to 2.3, P = 0.657).
Discussion
In this study, we investigated the long-term prognostic
impact of DTCs and CTCs before and after NACT in 236
patients with locally advanced breast cancer. We found
the presence of DTCs 12 months from the start of NACT
to be associated with a significantly elevated risk for sys-
temic relapse and death in univariate as well as in multi-
variate analyses. Our results are consistent with the results
of trials evaluating DTCs in the BM at follow-up in pri-
mary operable early breast cancer, including one smaller
study performed six months after chemotherapy [4,7].
These results highlight the potential importance of includ-
ing BM analyses as part of the follow-up for breast cancer
patients in general, and in particular, for patients with
locally advanced disease with their increased risk of
relapse.
According to our data, there was no association between
the DTC status before treatment and survival, when the
threshold of positivity was set at ≥ 1 DTC. This is not in
line with what other studies have shown [3]. This differ-
ence could be explained by the fact that all the patients
Table 3 Multivariate survival analyses
DFSª BCSSb OSb
HR 95% CI P HR 95% CI P HR 95% CI P
BM3-pos vs. BM3-neg 2.2 1.3-3.9 0.005 2.6 1.4-4.7 0.002 2.6 1.4-4.4 0.002
cN status (vs. N0) 0.053 0.032 0.047
cN1 2.0 1.0-3.8 0.040 2.3 1.1-4.8 0.019 2.2 1.1-4.3 0.024
cN 2-4 2.4 1.0-5.6 0.034 2.7 1.1-6.6 0.027 2.4 1.0-5.6 0.049
PgR-pos vs. PgR-neg 1.3 0.7-2.7 0.429 1.8 0.9-3.8 0.118 1.5 0.8-3.1 0.239
ER-pos vs. ER-neg 0.9 0.4-2.0 0.796 1.0 0.5-2.4 0.919 0.9 0.4-2.1 0.897
PB1-pos vs. PB1-neg 2.2 0.3-19.1 0.482 2.2 0.3-17.8 0.496
Grade 3 vs.grade 1-2 1.1 0.8-1.5 0.648 1.1 0.6-2.3 0.703 1.3 0.7-2.5 0.482
ªDisease-free survival (DFS) analyzed only in stage M0 patients.
bBreast cancer-free survival (BCSS) and overall survival (OS) analyzed in all patients.
Pos: positive; neg: negative; BM3: bone marrow aspiration pretreatment; cN: clinical node status; PgR: progesterone receptor; ER: estrogen receptor; PB1:
peripheral blood sampling pretreatment.
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Figure 3 Survival analyses according to disseminated tumor cell (DTC) number present. Kaplan-Meier plots for disease-free survival (DFS),
breast cancer specific survival (BCSS) and overall survival (OS) at the time of diagnosis/pretreatment according to number of DTCs detected
pretreatment (bone marrow aspiration 1 (BM1) (A, C, E) and BM3 (B, D, F). In the Kaplan-Meier plot shown in Figure 3A, no patients had ≥ 10
DTCs.
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included in our study were in a high-risk group, in con-
trast to the earlier stage breast cancer patients included in
most of the published reports so far. Locally advanced
breast cancer patients might have other biological factors
influencing their prognosis. However, with a cutoff of ≥ 3
DTCs, DTC status at BM1 affected both DFS and BCSS.
This indicates that patients with higher DTC loads were
not sufficiently treated by the given chemotherapy. More-
over, patients with disappearance of DTCs between BM1
and BM3 clearly show improved survival, compared to
patients with persisting DTCs. This is probably due to the
fact that DTC results at BM1 does not account for the
influence of chemotherapy, further emphasizing the
importance of performing DTC analyses after completion
of (and during) chemotherapy. Also, the switch from nega-
tivity at BM1 to positivity at BM3, clearly results in a
worse prognosis, in line with patients being both positive
at BM1 and BM3. These observations can be explained by
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and overall survival (OS) according to the results of the combination of bone marrow disseminated tumor cell (DTC) status at BM1 and BM3.
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the presence of low number of therapy-resistant DTCs
(either below or above the detection limit), which will be
detected as persistent DTCs at follow-up. This is also sup-
ported by an earlier publication from our group [5].
Decisions about systemic treatment are increasingly
based on more detailed knowledge of the primary tumor
characteristics like amplification or over-expression of
HER2 [29] and hormone receptor positivity [30], which
improves the patient outcomes. HER2 status was not ana-
lyzed, as the current study was performed prior to imple-
mentation of trastuzumab treatment and thus, routine
HER2 testing, in the primary setting. However, with up-
to-date systemic treatment we still experience only about
40 to 60% relative reduction in relapse. This indicates,
especially in high risk groups, that a large number of
patients still are insufficiently treated. As DTC status iden-
tifies a high risk group after completion of chemotherapy,
DTC analysis during follow-up may open opportunities
for introducing additional treatment. Hence, clinical trials
should be designed to investigate the effect of secondary
adjuvant treatment for DTC-positive patients in this
window of opportunity with no overt metastases, only the
presence of isolated tumor cells.
Pathological complete response (pCR) is a predictor of
improved outcome in patients with locally advanced
breast cancer [18]. In the current study, CR was not asso-
ciated with improved survival, probably due to statistical
limitations caused by the low CR rate achieved with the
chemotherapy regimens. In addition, the use of clinical
response criteria might affect the association between
response and clinical outcome. Furthermore, no associa-
tion between the detection of DTCs after NACT and CR
was found (Table 1), which is in agreement with other
published studies [31]. Again, the low CR rate might
influence the possibility to show association between
DTC status and CR. No significant difference in the fre-
quency of DTC positivity was observed between BM1
and BM3. There was a trend towards association between
DTC presence at BM1 and BM3 (P = 0.09) (Table 1). For
the patients that had both a conclusive BM1 and BM2
result, we did not observe any change in the frequency of
DTC positivity compared to BM1 (11 out of 66 positive
at both time points) (Table 1). Others have performed
serial BM aspiration, showing reduction in DTCs after
systemic treatment, followed by increased positivity at
later time points [32]. Different sensitivity in the DTC
detection methods might cause differences between stu-
dies, and for the present study, the number of BM2 cases
restricts the interpretation.
Our data, although limited by a low number of positive
samples, also indicate that analyzing PB for CTCs at the
time of diagnosis could identify high risk patients. This is
in line with the results from other studies in early breast
cancer [6,14,16]. However, CTC positivity was only
associated with reduced BCSS and did not affect DFS
(Table 2). As the analysis of BCSS (and OS) also included
the stage M1 patients who were excluded from the DFS
analysis, differences in the results might be expected.
Indeed, analysis of BCSS without the M1 patients did not
show a significant difference between CTC-positive and
CTC-negative patients (Table 2, footnote). The low sensi-
tivity of the present CTC analysis restricts further inter-
pretation of the results. The study was performed with
an ICC-based technique for detection of tumor cells both
in bone marrow and peripheral blood, as this was the
available and most standardized method at the time of
the study initiation. The sample size used for detection of
DTCs and CTCs was the same. As the concentration of
CTCs is very low, increased sensitivity methods are prob-
ably needed. Today there are several technologies for
CTC detection with higher sensitivity, including immu-
nomagnetic separation, higher blood sample volumes and
reverse transcriptase polymerase chain reaction (RT-
PCR) [14,17,33]. It is likely that the number of CTCs
detected in the samples from the patients in our study
would have been higher if one of these technologies were
utilized. Despite this, we observed an association between
CTC and DTC presence both before NACT and one year
after the start of NACT (Table 1). Similar findings have
been published from other groups [34,35]. The prognos-
tic impact of DTCs compared to CTCs varies between
studies [6,35-37]. This could partly be explained by the
discrepancies in the detection methods causing differ-
ences in sensitivity and specificity, and possibly different
relevance of DTCs and CTCs depending on the breast
tumor subtype [14]. DTCs and CTCs might possibly be
two biologically different entities, the DTCs may stay
dormant in the BM for several years, and the CTCs
might be migrating from a more actively proliferating cell
clone in the tumor. Hence, the DTCs could be expected
to be more predictive of the risk for later development of
metastases or relapse [35].
Molecular characterization of the primary tumor and
the corresponding DTCs and CTCs is possible both at
the protein, RNA and DNA level [38-40]. Recently,
results from whole genome-based molecular characteri-
zation of single tumor cells, have also been reported
[41,42]. These methods may provide information about
the metastatic potential of the single tumor cell and their
tumor initiating capacity, as well as characteristics of dor-
mant tumor cells. The opportunity to characterize these
cells opens possibilities for identification of markers
which may guide treatment decisions [43].
Conclusions
In conclusion, this study shows that for patients with
locally advanced breast cancer, the presence of occult
tumor cells in blood or bone marrow predicts poor
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clinical outcome. Especially, the persistence of DTCs
after neoadjuvant therapy and surgery is a strong prog-
nostic marker. Further characterization of DTCs is still
needed, as well as improved biological understanding of
what determines the presence of DTCs. This may lead
to establishment of more efficient adjuvant therapies for
DTC-positive patients in the future.
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